June 2021
Volume 62, Issue 8
Open Access
ARVO Annual Meeting Abstract  |   June 2021
Real-life outcomes of dexamethasone intravitreal implant (Ozurdex) in diabetic macular oedema for treatment-naive eyes compared to anti-VEGF non-responders at three months post-treatment
Author Affiliations & Notes
  • Ali Essam Ghareeb
    Sunderland Eye Infirmary, Sunderland, Tyne and Wear, United Kingdom
    Biosciences Institute, Newcastle University, Newcastle upon Tyne, Tyne and Wear, United Kingdom
  • Tiffany Lau
    Sunderland Eye Infirmary, Sunderland, Tyne and Wear, United Kingdom
  • Mila Kishikova
    Sunderland Eye Infirmary, Sunderland, Tyne and Wear, United Kingdom
  • Ajay Kotagiri
    Sunderland Eye Infirmary, Sunderland, Tyne and Wear, United Kingdom
  • Ibrahim Masri
    Sunderland Eye Infirmary, Sunderland, Tyne and Wear, United Kingdom
  • Jonathan Smith
    Sunderland Eye Infirmary, Sunderland, Tyne and Wear, United Kingdom
  • Deepali Varma
    Sunderland Eye Infirmary, Sunderland, Tyne and Wear, United Kingdom
  • David Steel
    Sunderland Eye Infirmary, Sunderland, Tyne and Wear, United Kingdom
    Biosciences Institute, Newcastle University, Newcastle upon Tyne, Tyne and Wear, United Kingdom
  • Maged Habib
    Sunderland Eye Infirmary, Sunderland, Tyne and Wear, United Kingdom
  • Footnotes
    Commercial Relationships   Ali Ghareeb, None; Tiffany Lau, None; Mila Kishikova, None; Ajay Kotagiri, None; Ibrahim Masri, None; Jonathan Smith, None; Deepali Varma, None; David Steel, None; Maged Habib, None
  • Footnotes
    Support  NIHR Academic Clinical Fellowship
Investigative Ophthalmology & Visual Science June 2021, Vol.62, 1047. doi:
  • Views
  • Share
  • Tools
    • Alerts
      ×
      This feature is available to authenticated users only.
      Sign In or Create an Account ×
    • Get Citation

      Ali Essam Ghareeb, Tiffany Lau, Mila Kishikova, Ajay Kotagiri, Ibrahim Masri, Jonathan Smith, Deepali Varma, David Steel, Maged Habib; Real-life outcomes of dexamethasone intravitreal implant (Ozurdex) in diabetic macular oedema for treatment-naive eyes compared to anti-VEGF non-responders at three months post-treatment. Invest. Ophthalmol. Vis. Sci. 2021;62(8):1047.

      Download citation file:


      © ARVO (1962-2015); The Authors (2016-present)

      ×
  • Supplements
Abstract

Purpose : Diabetic macular oedema (DMO) is a common cause of vision loss in the working-age population. Ozurdex is used as a first or second line treatment for DMO. The functional and structural outcomes of treatment have been reported, however its relative efficacy after anti-VEGFs have failed is yet to be determined. The purpose of our study is to present real-life data of functional and structural outcomes in patients with DMO treated with Ozurdex first line as compared to Anti-VEGF non-responders at 3 months after first Ozurdex injection.

Methods : Retrospective analysis for all patients with DMO treated with Ozurdex implant between January 2016 to October 2019, at Sunderland Eye Infirmary, UK. The full cohort was subclassified to treatment-naive eyes and anti-VEGF non-responders’ eyes. The primary outcome measures were observed at 3 months post implant for the 2 groups, and included mean changes in best-corrected visual acuity (BCVA) and central macular thickness (CMT) from baseline. Secondary outcomes included proportions of patients with ≥10 letters gain or loss; ≥20% of CMT gain or loss and final BCVA and CMT. Baseline characteristics of both treatment-naive eyes and Anti-VEGF non-responders were compared including age, sex, diabetes duration, DMO duration, comorbidities, baseline vision and CMT.

Results : We included 89 eyes (74 patients), with 30 treatment naïve eyes and 59 anti-VEGF non-responders. The improvement in VA in the first group was 5.7 and 5.3 letters in the second group (p=0.85), with the final VA of 63.9 and 58.2 letters, respectively (p=0.13). CMT decreased in the naive and previous anti-VEGF groups at three months (-83.21uM vs -88.47uM, respectively; p=0.85). In the treatment naive versus previous anti-VEGF groups, we found ≥10 letters gain was experienced in 26.67% and 20.69% (p=0.82), ≥10 letters loss in 3.33% and 5.17% (p=0.82), and ≥20% of CMT reduction in 48.28% and 44.07% (p=0.82), respectively.

Conclusions : Our study shows no statistically significant difference in functional or structural outcomes between treatment-naive and previous anti-VEGF groups at three months. These results confirm that the short-term efficacy of Ozurdex implant is comparable both as a first or second line of treatment in patients with DMO.

This is a 2021 ARVO Annual Meeting abstract.

×
×

This PDF is available to Subscribers Only

Sign in or purchase a subscription to access this content. ×

You must be signed into an individual account to use this feature.

×